0.00Open0.05Pre Close0 Volume53 Open Interest0.50Strike Price0.00Turnover0.00%IV36.62%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-28DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma14.20Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ocugen Stock Discussion
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Ocu200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a positive 2-year safety and efficacy update for the Phase 1...
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Monday, 13th January at 6:30 am
• 100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years
• 100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only p...
No comment yet